New drug combo shows promise in Hard-to-Treat cancers

NCT ID NCT03156114

Completed Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two experimental drugs (BI 754111 and BI 754091) that help the immune system attack cancer. It included 172 adults with advanced solid tumors, including non-small cell lung cancer that had returned after prior treatment. The first part found the safest dose, and the second part checked if the combination could shrink tumors. Treatment was given every 3 weeks for up to one year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG NEOPLASMS

Contacts and locations

Locations

BioVirtus Research Site Sp. z o.o.

Józefów, 05-410, Poland
Cross Cancer Institute (University of Alberta)

Edmonton, Alberta, T6G 1Z2, Canada
Florida Cancer Specialists

Sarasota, Florida, 34232, United States
Froedtert and The Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Hospital General Universitario Gregorio Marañón

Madrid, 28007, Spain
Hospital Politècnic La Fe

Valencia, 46026, Spain
Hospital Universitari Dexeus

Barcelona, 08028, Spain
Hospital Universitario HM Sanchinarro

Madrid, 28050, Spain
John Theurer Cancer Center

Hackensack, New Jersey, 07601, United States
Oncology Center-Maria Sklodowska-Curie Institute

Warsaw, 02-781, Poland
Princess Margaret Cancer Centre

Toronto, Ontario, M5G 1Z9, Canada
Sarah Cannon Research Institute

London, W1G 6AD, United Kingdom
Stephenson Cancer Center

Oklahoma City, Oklahoma, 73104, United States
Tennessee Oncology, PLLC

Nashville, Tennessee, 37203, United States
University of Miami

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.